Evaluating Gene Therapy and Immunotherapy for Cancer and Genetic Disorders
DOI:
Abstract
Gene therapy and immunotherapy have emerged as revolutionary treatments in medicine, offering hope for previously untreatable diseases, particularly cancer and genetic disorders. This study aims to analyze the progress and challenges in gene therapy and immunotherapy in the US healthcare system during 2022 and 2023, with a focus on their effectiveness, barriers to implementation, and regulatory hurdles. The methodology used in this study is a descriptive qualitative approach, using literature reviews, case study analysis, and data from clinical trials at institutions such as the NIH and Mayo Clinic. The findings highlight significant advances in gene therapies such as CRISPR for genetic disorders and cancer treatment, as well as the success of CAR-T cell therapy in hematologic cancers. However, both therapies face challenges, including high treatment costs, regulatory delays, and limited accessibility. Despite these challenges, this study highlights the promising future of these therapies, with advances in gene editing and immunotherapy expected to expand their applications. Future research should focus on long-term safety and efficacy, cost reduction strategies, and improved delivery systems for both therapies. Addressing these gaps will be critical to the widespread adoption of gene therapy and immunotherapy in clinical practice.
Downloads
Views : 160
Downloads : 123
References
A. R. Kumar, A. R. Devan, B. Nair, B. S. Vinod, and L. R. Nath, “Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets,” Molecular Biology Reports, vol. 48, no. 12, pp. 8075–8095, 2021.
F. Uddin, C. M. Rudin, and T. Sen, “CRISPR gene therapy: applications, limitations, and implications for the future,” Frontiers in Oncology, vol. 10, 2020.
A. N. Ansori, Y. Antonius, R. J. Susilo, S. Hayaza, V. D. Kharisma, A. A. Parikesit, R. Zainul, V. Jakhmola, T. Saklani, M. Rebezov, M. E. Ullah, N. Maksimiuk, M. Derkho, and P. Burkov, “Application of CRISPR-Cas9 genome editing technology in various fields: A review,” Narra Journal, vol. 3, no. 2, 2023.
A. I. Stoumpos, F. Kitsios, and M. A. Talias, “Digital transformation in healthcare: technology acceptance and its applications,” International Journal of Environmental Research and Public Health, 2023.
A. I. Stoumpos, F. Kitsios, and M. A. Talias, “Digital transformation in healthcare: technology acceptance and its applications,” International Journal of Environmental Research and Public Health, vol. 20, no. 4, 2023.
S. A. Alowais, S. S. Alghamdi, N. Alsuhebany, et al., “Revolutionizing healthcare: the role of artificial intelligence in clinical practice,” BMC Medical Education, vol. 23, 2023.
H. Li, Y. Yang, W. Hong, M. Huang, M. Wu, and X. Zhao, “Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects” Signal Transduction and Targeted Therapy, vol. 5, no. 1, 2020.
J. T. Bulcha, Y. Wang, H. Ma, et al., “Viral vector platforms within the gene therapy landscape,” Signal Transduction and Targeted Therapy, vol. 6, 2021.
M. Al-Haideri, S. B. Tondok, S. H. Safa, A. H. Maleki, S. Rostami, A. T. Jalil, M. E. Al-Gazally, F. Alsaikhan, J. A. Rizaev, T. A. M. Mohammad, and S. Tahmasebi, “CAR-T cell combination therapy: the next revolution in cancer treatment,” Cancer Cell International, vol. 22, no. 1, 2022.
V. Gowd, A. Ahmad, M. Tarique, M. Suhail, T. A. Zughaibi, S. Tabrez, and R. Khan, “Advancement of cancer immunotherapy using nanoparticles-based nanomedicine,” Seminars in Cancer Biology, vol. 86, Part 2, pp. 624–644, 2022.
P. Sharma, S. Goswami, D. Raychaudhuri, B. A. Siddiqui, P. Singh, A. Nagarajan, J. Liu, S. K. Subudhi, C. Poon, K. L. Gant, S. M. Herbrich, S. Anandhan, S. Islam, M. Amit, G. Anandappa, and J. P. Allison, “Immune checkpoint therapy-current perspectives and future directions,” Cell, vol. 186, no. 8, pp. 1652–1669, 2023.
K. J. Mitchell, C. B. Chan, and M. S. Roy, “CAR-T cell therapy in hematological cancers: Current status and future directions,” Journal of Hematology and Oncology, vol. 13, no. 5, pp. 30-40, 2023.
S. A. Beheshti, K. Shamsasenjan, M. Ahmadi, and B. Abbasi, “CAR Treg: A new approach in the treatment of autoimmune diseases,” International Immunopharmacology, vol. 102, 2022.
G. Sharma, A. R. Sharma, M. Bhattacharya, S. S. Lee, and C. Chakraborty, “CRISPR-Cas9: A preclinical and clinical perspective for the treatment of human diseases,” Molecular Therapy, vol. 29, no. 2, pp. 571–586, 2021.
K. M. Maalej, M. Merhi, V. P. Inchakalody, et al., “CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances,” Molecular Cancer, vol. 22, 2023.
Y. Wang and A. Minden, “Current molecular combination therapies used for the treatment of breast cancer,” International Journal of Molecular Sciences, vol. 23, no. 19. 2022.
T. Fan, M. Zhang, J. Yang, Z. Zhu, W. Cao, and C. Dong, “Therapeutic cancer vaccines: advancements, challenges, and prospects,” Signal Transduction and Targeted Therapy, vol. 8, no. 1, 2023.
M. Chehelgerdi and M. Chehelgerdi, “The use of RNA-based treatments in the field of cancer immunotherapy,” Molecular Cancer, vol. 22, 2023.
